美國(guó)IB(Indoor Biotechnologies)  www.inbio.com
IB公司是一家專業(yè)開發(fā)生產(chǎn)用于研究哮喘以及其他過敏性疾病的免疫診斷和相關(guān)生物學(xué)檢測(cè)產(chǎn)品的生物技術(shù)公司，IB由兩家子公司組成，一家是位于美國(guó)弗吉尼亞的INDOOR Biotechnologies Inc. (IBI)，另一家為位于英國(guó)INDOOR Biotechnologies Limited (IBL)。IB的創(chuàng)始人Martin D. Chapman博士曾經(jīng)是美國(guó)弗吉尼亞大學(xué)的醫(yī)學(xué)和微生物教授，并曾經(jīng)擔(dān)任過美國(guó)NIH、環(huán)保署已及多家生物公司的顧問科學(xué)家。做為環(huán)境過敏原（變應(yīng)原）檢測(cè)系統(tǒng)的領(lǐng)導(dǎo)公司，IB生產(chǎn)的一系列過敏原研究和檢測(cè)用抗體擁有來自美國(guó)弗吉尼亞大學(xué)的獨(dú)家專利，能夠用于檢測(cè)屋塵螨、貓、狗、蟑螂和真菌來源過敏原。
IB開發(fā)生產(chǎn)面向?qū)嶒?yàn)室用戶的過敏原Elisa檢測(cè)試劑盒以及面向家庭用戶的過敏原快速檢測(cè)試劑盒，利用后者用戶在家中即可于10分鐘之內(nèi)檢測(cè)出屋塵螨抗原。這些檢測(cè)系統(tǒng)可用于對(duì)過敏原環(huán)境暴露水平的評(píng)估，也能讓用戶對(duì)使用的過敏原隔離清除程序、相關(guān)產(chǎn)品和設(shè)備的有效性進(jìn)行可靠的評(píng)估，還可應(yīng)用于過敏原標(biāo)準(zhǔn)化以及相關(guān)產(chǎn)品的研究開發(fā)。

IB還開發(fā)出了天然和重組的過敏原產(chǎn)品線，可用于研究和開發(fā)新的過敏原診斷和過敏性疾病的治療策略，目前包括最重要的屋塵螨、貓和蟑螂來源的主要過敏原。

IB的技術(shù)和產(chǎn)品已經(jīng)在全球范圍內(nèi)被廣泛使用，相關(guān)的科學(xué)論文已在超過250種科學(xué)出版物上發(fā)表。除提供產(chǎn)品以外IB還提供過敏原分析服務(wù)、合同研究服務(wù)以及專業(yè)培訓(xùn)服務(wù)。

Indoor Biotechnologies (IB) is an immunodiagnostics and biotechnology company specializing in manufacturing innovative products for investigating environmental and immunologic aspects of asthma and allergic diseases. The company's technology includes a comprehensive set of monoclonal antibodies for the detection of house dust mite, cat, dog, cockroach and fungal allergens.

IB has a worldwide exclusive licence to market these antibodies from the University of Virginia Patent Foundation. IB has developed a range of innovative allergen detection systems, including laboratory based ELISA and a consumer based rapid test kit, which detects mite allergen in the home within 10 minutes. These systems provide a complete range of tests for assessing environmental exposure to indoor allergens; for testing the efficacy of allergen avoidance procedures, products and devices, for allergen standardization and product development.

IB is the world leader in environmental allergen detection systems. IB technology is used worldwide and has been reported in over 250 scientific publications on indoor allergens. IB operates an INDOOR?Allergen Analysis Service, Contract Research Services and Professional Training Courses. IB introduced natural and recombinant allergens as a new product line for research use and for developing new strategies for allergy diagnosis and treatment. This range of products currently includes the most important dust mite, cat and cockroach allergens. IB has an extensive product pipeline and ambitious plans for developing consumer based allergy diagnostic devices and environmental products.

IB was founded by Dr. Martin D. Chapman, formerly Professor of Medicine and Microbiology at the University of Virginia and a member of the UVA Asthma and Allergic Diseases Center. Dr. Chapman is a Fellow of the American Academy of Allergy, Asthma and Immunology and has served as a consultant to the U.S. National Institutes of Health, the Environmental Protection Agency, and several biotechnology and environmental products companies. IB is organized as two affiliated companies, INDOOR Biotechnologies Inc. (IBI), located in Charlottesville, Virginia, USA, and INDOOR Biotechnologies Limited (IBL) based in Warminster, UK. IBI carries out research, development and sales in the Americas and IBL handles sales, distribution and business development in Europe, the Far East, Australia and New Zealand.